Below are the first 10 and last 10 pages of uncorrected machine-read text (when available) of this chapter, followed by the top 30 algorithmically extracted key phrases from the chapter as a whole.
Intended to provide our own search engines and external engines with highly rich, chapter-representative searchable text on the opening pages of each chapter.
Because it is UNCORRECTED material, please consider the following text as a useful but insufficient proxy for the authoritative book pages.
Do not use for reproduction, copying, pasting, or reading; exclusively for search engines.
OCR for page 115
References
Andrus, J. K., V. Dietz, J. W. Fitzsimmons, and C. Castillo-Solorzano. 2006.
Accelerating policy, deployment, and access to new and underuti-
lized vaccines in developing countries. Harvard Health Policy Review
7(2):91–101.
Andrus, J. K., C. M. Toscano, M. Lewis, L. Oliveiria, A. M. Ropero, M. Dávila,
and J. W. Fitzsimmons. 2007. A model for enhancing evidence-based
capacity to make informed policy decisions on the introduction of
new vaccines in the Americas: PAHO’s ProVac initiative. Public Health
Reports 122(6):811–816.
Barron, F. H., and B. E. Barrett. 1996. The efficacy of SMARTER: Simple
multi-attribute rating technique extended to ranking. Acta Psycholog-
ica 93(1–3):23–36.
Berry, D. A., K. A. Cronin, S. K. Plevritis, D. G. Fryback, L. Clarke, M. Zelen,
J. S. Mandelblatt, A. Y. Yakovlev, J. D. F. Habbema, and E. J. Feuer. 2005.
Effect of screening and adjuvant therapy on mortality from breast can-
cer. New England Journal of Medicine 353(17):1784–1792.
Braithwaite, R., D. Meltzer, J. King Jr, D. Leslie, and M. S. Roberts. 2008.
What does the value of modern medicine say about the $50,000 per
quality-adjusted life-year decision rule? Medical Care 46(4):349–356.
Burchett, H. E. D., S. Mounier-Jack, U. K. Griffiths, and A. J. Mills. 2011.
National decision-making on adopting new vaccines: A systematic
review. Health Policy and Planning 27(Suppl 2):ii62–ii76.
Commission on Macroeconomics and Health. 2001. Macroeconomics and
health: Investing in health for economic development. Report of the Com-
mission on Macroeconomics and Health. Available at http://whqlibdoc.
who.int/publications/2001/924154550x.pdf (accessed April 16, 2012).
Daniels, N. 2007. Just health: Meeting health needs fairly. Cambridge: Cam-
bridge University Press.
115
OCR for page 116
116 RANKING VACCINES: A Prioritization Framework
Dyer, J. 1990. Remarks on the analytic hierarchy process. Management Sci-
ence 36:249–258.
Edwards, W. 1979. Multiattribute utility measurement: Evaluating deseg-
regation plans in a highly political context. In Evaluating interventions:
Pros and cons, edited by R. Perloff. Beverly Hills, CA: Sage. Pp. 13–54.
Edwards, W., and F. H. Barron. 1994. SMARTS and SMARTER: Improved
simple methods for multiattribute utility measurement. Organizational
Behavior and Human Decision Processes 60(3):306–325.
Edwards, W. and J. R. Newman. 1982. Multiattribute evaluation. Beverly
Hills, CA: Sage.
Epstein, J. M., J. Parker, D. Cummings, and R. A. Hammond. 2008. Coupled
contagion dynamics of fear and disease: Mathematical and computa-
tional explorations. PLoS One 3(12):e3955.
Feeny, D., G. Torrance, and W. Furlong. 1996. Health Utilities Index. In
Quality of life and pharmacoeconomics in clinical trials, 2nd ed., edited
by B. Spilker. Philadelphia: Lippincott–Raven Press. Pp. 239–252.
Fenwick, E., K. Claxton, and M. Sculpher. 2001. Representing uncertainty:
The role of cost-effectiveness acceptability curves. Health Economics
10(8):779–787.
Field, R. I., and A. L. Caplan. 2012. Evidence-based decision making for
vaccines: The need for an ethical foundation. Vaccine 30(6):1009–1013.
Fox-Rushby, J. A., and K. Hanson. 2001. Calculating and presenting dis-
ability adjusted life years (DALYs) in cost-effectiveness analysis. Health
Policy Plan 16(3):326–331.
Fryback, D. G. 2009. United States National Health Measurement Study,
2005–2006. In [Computer file]. National Archive of Computerized
Data on Aging: Inter-University Consortium for Political and Social
Research.
Fryback, D. G., N. C. Dunham, M. Palta, J. Hanmer, J. Buechner, D.
Cherepanov, S. Herrington, R. D. Hays, R. M. Kaplan, and T. G.
Ganiats. 2007. U.S. norms for six generic health-related quality-of-life
indexes from the National Health Measurement Study. Medical Care
45(12):1162–1170.
Fryback, D. G., M. Palta, D. Cherepanov, D. Bolt, and J. S. Kim. 2010. Com-
parison of 5 health-related quality-of-life indexes using item response
theory analysis. Medical Decision Making 30(1):5–15.
Garber, A., and C. Phelps. 1997. Economic foundations of cost-effectiveness
analysis. Journal of Health Economics 16(1):1–31.
Gates, B. 2010. The decade of vaccines. In The Financial Times Blog, http://
tinyurl.com/6o7fd92 (accessed March 1, 2012).
OCR for page 117
117
References
GAVI Alliance. 2010. Investing in immunisation through the GAVI alliance:
The evidence base. Geneva: GAVI Alliance.
Gold, M. R., D. L. Patrick, G. W. Torrance, D. G. Fryback, D. C. Hadorn, M. S.
Kamlet, N. Daniels, and M. C. Weinstein. 1996. Identifying and valuing
outcomes. In Cost effectiveness in health and medicine, edited by M. R.
Gold, J. E. Siegel, L. B. Russell, and M. C. Weinstein. New York: Oxford
University Press. Pp. 82–134.
Gold, M. R., D. Stevenson, and D. G. Fryback. 2002. HALYs and QALYs and
DALYs, Oh my: Similarities and differences in summary measures of
population health. Annual Review of Public Health 23(1):115–134.
Government of India. 2011. National vaccine policy. New Delhi: Ministry of
Health and Family Welfare.
Greco, M., and L. Hessel. 2008. Development and supply of vaccines: An
industry perspective. In New generation vaccines, 4th ed., edited by
M. Levine, G. Dougan, M. Good, M. Liu, G. Nabel, J. Nataro and R.
Rappuoli. New York: Informa Healthcare. Pp. 79–90.
HHS (U.S. Department of Health and Human Services). 2011. 2010 National
vaccine plan. Washington, DC: U.S. Department of the Health and
Human Services.
IOM (Institute of Medicine). 1985. New vaccine development: Establishing
priorities. Volume I, diseases of importance in the United States. Wash-
ington, DC: National Academy Press.
IOM. 1986. New vaccine development: Establishing priorities. Volume II, dis-
eases of importance in developing countries. Washington, DC: National
Academy Press.
IOM. 2000. Vaccines for the 21st century: A tool for decisionmaking. Wash-
ington, DC: National Academy Press.
Jefferson, T. 1806. A tribute of gratitude: To Edward Jenner. In Thomas
Jefferson: Letters 1743-1826. Charlottesville, VA: Electronic Text Cen-
ter, University of Virginia Library.
Jenner, E. 1801. On the origin of the vaccine inoculation. London: D.N. Shury.
Keefer, D. L., C. W. Kirkwood, and J. L. Corner. 2004. Perspective on deci-
sion analysis applications, 1990–2001. Decision Analysis 1(1):4–22.
Keeler, E. B., and S. Cretin. 1983. Discounting of life-saving and other non-
monetary effects. Management Science 29(3):300–306.
Keeney, R., and H. Raiffa. 1976. Decisions with multiple objectives: Prefer-
ences and value tradeoffs. New York: John Wiley & Sons, Inc.
Keeney, R., and G. Smith. 1982. Structuring objectives for evaluating pos-
sible nuclear material control and accounting regulations. IEEE Trans-
actions on Systems, Man and Cybernetics 12(6):743–750.
OCR for page 118
118 RANKING VACCINES: A Prioritization Framework
Keeney R, and D. von Winterfeldt. 2007. Practical value models. In
Advances in decision analysis, edited by W. Edwards, R. F. Miles, and D.
von Winterfeldt. New York: Cambridge University Press. Pp. 232–252.
Keeney, R., and D. von Winterfeldt. 2011. A value model for evaluating
homeland security decisions. Risk Analysis 31(9):1470–1487.
Keeney, R., T. McDaniels, and V. Ridge-Cooney. 1996. Using values in plan-
ning wastewater facilities for metropolitan seattle. Journal of the Amer-
ican Water Resources Association 32(2):293–303.
Keja, K., C. Chan, G. Hayden, and R. H. Henderson. 1988. Expanded pro-
gramme on immunization. World Health Statistics Quarterly. Rapport
Trimestriel de Statistiques Sanitaires Mondiales 41(2):59–63.
Knutti, R., R. Furrer, C. Tebaldi, J. Cermak, and G. A. Meehl. 2010. Chal-
lenges in combining projections from multiple climate models. Journal
of Climate 23(10):2739–2758.
Krantz, D. L,, D. Luce, P. Suppes, A. Tversky, 1971. Foundations of Measure-
ment, New York: Academic Press.
Luo, N., J. A. Johnson, J. W. Shaw, D. Feeny, and S. J. Coons. 2005. Self-
reported health status of the general adult U.S. population as assessed by
the EQ-5D and Health Utilities Index. Medical Care 43(11):1078–1086.
Luo, N., J. A. Johnson, J. W. Shaw, and S. J. Coons. 2009. Relative efficiency
of the EQ-5D, HUI2, and HUI3 index scores in measuring health bur-
den of chronic medical conditions in a population health survey in the
United States. Medical Care 47(1):53–60.
Manning, W. G., D. Fryback, and M. Weinstein. 1996. Reflecting uncertainty
in cost-effectiveness analysis. In Cost-effectiveness in health and medi-
cine, edited by M. R. Gold, J. E. Siegel, L. B. Russell and M. C. Weinstein.
New York: Oxford University Press. Pp. 247–275.
Mathers, C. D., A. D. Lopez, and C. J. L. Murray. 2006. The burden of dis-
ease and mortality by condition: Data, methods, and results for 2001.
In Global burden of disease and risk factors, edited by A. D. Lopez, C. D.
Mathers, M. Ezzati, D. T. Jamison, and C. J. L. Murray. Washington,
DC: World Bank. Pp. 45–93.
McNeil, D. 2012. Bill Gates donates $750 million to shore up disease-
fighting fund. New York Times, January 26.
Meckley, L. M., D. Greenberg, J. T. Cohen, and P. J. Neumann. 2010. The
adoption of cost-effectiveness acceptability curves in cost-utility analy-
ses. Medical Decision Making 30(3):314–319.
Molinari, N. A., I. R. Ortega-Sanchez, M. L. Messonnier, W. W. Thompson,
P. M. Wortley, E. Weintraub, and C. B. Bridges. 2007. The annual impact
of seasonal influenza in the US: Measuring disease burden and costs.
Vaccine 25(27):5086–5096.
OCR for page 119
119
References
Murray, C. J. L., and A. D. Lopez. 1996. The global burden of disease: A com-
prehensive assessment of mortality and disability from diseases, inju -
ries, and risk factors in 1990 and projected to 2020. Vol. 1, Global burden
of disease and injury series. Cambridge, MA: Harvard School Public
Health/WHO/World Bank.
Murray, C. J. L., and A. D. Lopez. 2000. Progress and directions in refining
the global burden of disease approach: A response to Williams. Health
Economics 9(1):69–82.
Phelps, C. E., and A. I. Mushlin. 1988. Focusing technology assessment
using medical decision theory. Medical Decision Making 8(4):279–289.
Plotkin, S., S. Sepe, and M. Myers. 2000. Institute of Medicine report: “Vac -
cines for the 21st century,” analysis and action plan for the National
Vaccine Advisory Committee; prepared for NVAC Subcommittee on
Future Vaccines. http://www.hhs.gov/nvpo/nvac/vaccines21cer.html
(accessed January 26, 2012).
Poland, G. A., and E. K. Marcuse. 2011. Developing vaccine policy: Attri-
butes of “just policy” and a proposed template to guide decision and
policy making. Vaccine 29(44):7577–7578.
Ramsey, S., R. Willke, A. Briggs, R. Brown, M. Buxton, A. Chawla, J. Cook,
H. Glick, B. Liljas, D. Petitti, and S. Reed. 2005. Good research prac-
tices for cost-effectiveness analysis alongside clinical trials: The ISPOR
RCT–CEA Task Force Report. Value Health 8(5):521–533.
Rappuoli, R., and A. Aderem. 2011. A 2020 vision for vaccines against HIV,
tuberculosis and malaria. Nature 473(7348):463–469.
Rappuoli, R., H. Miller, and S. Falkow. 2002. The intangible value of vac-
cination. Science 297(5583):937–939.
Rappuoli, R., C. Mandl, S. Black, and E. De Gregorio. 2011. Vaccines for
the twenty-first century society. Nature Reviews Immunology 11(12):
865–872.
Rardin, R. 1997. Optimization in operations research. Upper Saddle River,
NJ: Prentice Hall.
Saaty, T., 1987. Concepts, theory and techniques: Rank generation, preser-
vation, and reversal in the Analytic Hierarchy Process. Decision Sci-
ences 18:157–177.
Stern, A., and H. Markel. 2005. The history of vaccines and immunization:
Familiar patterns, new challenges. Health Affairs 24(3):611–621.
von Winterfeldt, D., and W. Edwards. 1986. Decision analysis and behavioral
research. Vol. 1. New York: Cambridge University Press.
Weinstein, M. C. 2008. How much are Americans willing to pay for a
quality-adjusted life year? Medical Care 46(4):343–345.
OCR for page 120
120 RANKING VACCINES: A Prioritization Framework
WHO (World Health Organization). 2003. Making choices in health: WHO
guide to cost-effectiveness analysis. Edited by T. Tan-Torres Edejer, R.
Baltussen, T. Adam, R. Hutubessy, A. Acharya, D. B. Evans, and C. J. L.
Murray. Geneva: World Health Organization.
WHO. 2004. Global burden of disease 2004 update: Disability weights for
diseases and conditions. Geneva: World Health Organization.
WHO. 2006. Global immunization vision and strategy. www.who.int/immu-
nization/givs/en/index.html.
WHO. 2010. The Initiative for Vaccine Research, strategic plan 2010-2020.
Geneva: Initiative for Vaccine Research, Department of Immunization,
Vaccines and Biologicals.
